Myeloperoxidase: a new target for the treatment of stroke?

• Published in: Neural regeneration research 2022-08, Vol.17 (8), p.1711-1716
• Main Authors: Wang, Yun-Chang, Lu, Yu-Bao, Huang, Xiao-Lan, Lao, Yong-Feng, Zhang, Lu, Yang, Jun, Shi, Mei, Ma, Hai-Long, Pan, Ya-Wen, Zhang, Yi-Nian
• Format: Article
• Language: English
• Subjects: blood-brain barrier; hemorrhagic stroke; inflammation; ischemic stroke; microglia; myeloperoxidase; neutrophils; secondary brain injury; stroke; Review
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.332130

Myeloperoxidase is an important inflammatory factor in the myeloid system, primarily expressed in neutrophils and microglia. Myeloperoxidase and its active products participate in the occurrence and development of hemorrhagic and ischemic stroke, including damage to the blood-brain barrier and brain. As a specific inflammatory marker, myeloperoxidase can be used in the evaluation of vascular disease occurrence and development in stroke, and a large amount of experimental and clinical data has indicated that the inhibition or lack of myeloperoxidase has positive impacts on stroke prognosis. Many studies have also shown that there is a correlation between the overexpression of myeloperoxidase and the risk of stroke. The occurrence of stroke not only refers to the first occurrence but also includes recurrence. Therefore, myeloperoxidase is significant for the clinical evaluation and prognosis of stroke. This paper reviews the potential role played by myeloperoxidase in the development of vascular injury and secondary brain injury after stroke and explores the effects of inhibiting myeloperoxidase on stroke prognosis. This paper also analyzes the significance of myeloperoxidase etiology in the occurrence and development of stroke and discusses whether myeloperoxidase can be used as a target for the treatment and prediction of stroke.